Tiara Bunga Mayang Permata

Dr. Tiara Bunga Mayang Permata

Universitas Indonesia
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2019 in Oncogene
Verified
Journal Article
Closed access
PDF file
TPTiara Bunga Mayang Permata
Tiara Bunga Mayang Permata
YHYoshihiko Hagiwara
Yoshihiko Hagiwara
HSHiro Sato
Hiro Sato
TYTakaaki Yasuhara
Takaaki Yasuhara
TOTakahiro Oike
Takahiro Oike
ASAtsushi Shibata
Atsushi Shibata

7 February 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
ENEndang Nuryadi
Endang Nuryadi
TPTiara Bunga Mayang Permata
Tiara Bunga Mayang Permata
SKShuichiro Komatsu
Shuichiro Komatsu
TOTakahiro Oike
Takahiro Oike
TNTakashi Nakano
Takashi Nakano
Inter-assay precision of clonogenic assays for radiosensitivity in cancer cell line A549 Inter-assay precision of clonogenic assays for radiosensitivity in cancer cell line A549

19 May 2022 in Molecular Cell
Verified
Journal Article
Closed access
YUYuki Uchihara
Yuki Uchihara
TPTiara Bunga Mayang Permata
Tiara Bunga Mayang Permata
HSHiro Sato
Hiro Sato
RKReika Kawabata-Iwakawa
Reika Kawabata-Iwakawa
SKSayako Katada
Sayako Katada
ASAtsushi Shibata
Atsushi Shibata

6 April 2021 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
YMYasumasa Mori
Yasumasa Mori
HSHiro Sato
Hiro Sato
TKTakuya Kumazawa
Takuya Kumazawa
TPTiara Bunga Mayang Permata
Tiara Bunga Mayang Permata
YYYuya Yoshimoto
Yuya Yoshimoto
ASAtsushi Shibata
Atsushi Shibata
Radiotherapy induces an immune response in the cancer microenvironment that may influence clinical outcome. The present study aimed to analyse the alteration of CD8+ T‑cell infiltration and programmed death‑ligand 1 (PD‑L1) expression following radiotherapy in clinical samples from patients with uterine cervical squamous cell carcinoma. Additionally, the current study sought to analyse the association between these immune responses and clinical outcomes. A total of 75 patients who received either definitive chemoradiotherapy or radiotherapy were retrospectively analyzed. CD8+ T‑cell infiltration and PD‑L1 expression were determined by immunohistochemistry using biopsy specimens before radiotherapy (pre‑RT) and after 10 Gy radiotherapy (post‑10 Gy). The PD‑L1+ rate was significantly increased from 5% (4/75) pre‑RT to 52% (39/75) post‑10 Gy (P<0.01). Despite this increase in the PD‑L1+ rate post‑10 Gy, there was no significant association between both pre‑RT and post‑10 Gy and overall survival (OS), locoregional control (LC) and progression‑free survival (PFS). On the other hand, the CD8+ T‑cell infiltration density was significantly decreased for all patients (median, 23.1% pre‑RT vs. 16.9% post‑10 Gy; P=0.038); however, this tended to increase in patients treated with radiotherapy alone (median, 17.7% pre‑RT vs. 24.0% post‑10 Gy; P=0.400). Notably, patients with high CD8+ T‑cell infiltration either pre‑RT or post‑10 Gy exhibited positive associations with OS, LC and PFS. Thus, the present analysis suggested that CD8+ T‑cell infiltration may be a prognostic biomarker for patients with cervical cancer receiving radiotherapy. Furthermore, immune checkpoint inhibitors may be effective in patients who have received radiotherapy, since radiotherapy upregulated PD‑L1 expression in cervical cancer specimens.

8 September 2021 in Immunological Medicine
Verified
Journal Article
Open access
AHAgustinus Darmadi Hariyanto
Agustinus Darmadi Hariyanto
TPTiara Bunga Mayang Permata
Tiara Bunga Mayang Permata
SGSoehartati Gondhowiardjo
Soehartati Gondhowiardjo
Not all T cells are effector cells of the anti-tumor immune system. One of the subpopulations of CD4+ T cells that express CD25+ and the transcription factor FOXP3, known as Regulator T cells (TReg), plays an essential role in maintaining tolerance and immune homeostasis preventing autoimmune diseases, minimalize chronic inflammatory diseases by enlisting various immunoregulatory mechanisms. The balance between effector T cells (Teff) and regulator T cells is crucial in determining the outcome of an immune response. Regarding tumors, activation or expansion of TReg cells reduces anti-tumor immunity. TReg cells inhibit the activation of CD4+ and CD8+ T cells and suppress anti-tumor activity in the tumor microenvironment. In addition, TReg cells also promote tumor angiogenesis both directly and indirectly to ensure oxygen and nutrient transport to the tumor. There is accumulating evidence showing a positive result that removing or suppressing TReg cells increases anti-tumor immune response. However, depletion of TReg cells will cause autoimmunity. One strategy to improve or restore tumor immunity is targeted therapy on the dominant effector TReg cells in tumor tissue. Various molecules such as CTLA-4, CD4, CD25, GITR, PD-1, OX40, ICOS are in clinical trials to assess their role in attenuating TReg cells’ function.

1 December 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
NPNovianti Qurnia Putri
Novianti Qurnia Putri
TPTiara Bunga Mayang Permata
Tiara Bunga Mayang Permata
NWNi Ayu Wulandari
Ni Ayu Wulandari
HHHandoko Handoko
Handoko Handoko
ENEndang Nuryadi
Endang Nuryadi
SGSoehartati Gondhowiardjo
Soehartati Gondhowiardjo
Cervical cancer is the one of the most common gynecology malignancies in the world. National Comprehensive Cancer Network (NCCN) guidelines on cervical cancer are widely adopted as national guidelines and clinical practice guidelines. These guidelines are constantly being updated but their effectiveness has not been questioned. Therefore, we conducted a systematic review to assess outcomes with/without guideline adherence in the published studies. This systematic review was conducted according to PRISMA statement. Searching with strategy on PubMed, ProQuest, Scopus, and Wiley databases resulted in three studies that met all criteria, thus assessed further with Newcastle-Ottawa scale, and assessed qualitatively. All three studies adopt NCCN guidelines. We found that the proportion of adherence to cervical cancer treatment guidelines was low, ranging from 42% to 54%, with violations occurring at various clinical stages. One study stated that early stage cervical cancer was more likely to receive guideline adherence (adjusted OR=5.48; 95%CI: 1.94– 15.5; p=0.001) than advanced stage. There was a higher five-year survival of cervical cancer patients in the guideline-adhering group than in the nonadhering group. In all three studies, survival in the adherent group was reported as big as 88%, 79%, and 93%, respectively, compared to nonadherent group with 56%, 78%, and 88.1%respectively (p< 0.05). One study stated that adherence to guidelines could reduce cervical cancer mortality on stage I and II by 0.22 times (p< 0.05). As the conclusion, adherence to guidelines increases survival rates. In the early stages, there are differences in survival.